Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, the answers, the terms or the safety information page. 1 more criterion also fails; see the table below.
At a glance
Vytora HealthTelehealth service
6/8criteria passed
Price
Semaglutide $179 a month or $149 on a 3-month plan, tirzepatide $249
Sells
compounded semaglutide, compounded tirzepatide, and 4 more
Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.
A telehealth service selling compounded semaglutide and tirzepatide, compounded sermorelin and NAD+ injections, and brand Mounjaro and Zepbound at retail prices. A named Florida medical group prescribes and two filling pharmacies are named, and the site prints no address for the company.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSAll clinical services come from Wasef Health, PC, a medical group in Pinellas Park, Florida, and a licensed provider reviews the medical history and prescribes only if medication is appropriate.Source: Vytora Health's website; Vytora Health's about page.
S2PASSThe start button opens a screen that asks for an email address or a new account, with no cart and no payment form, and the site says a licensed provider reviews the medical history before any prescription.Source: Vytora Health's sign-up site; Vytora Health's website.
S3PASSThe about page and the home page answers name two compounding pharmacies: Vials Pharmacy at 6220 Westpark Drive, Houston, Texas, and Hallandale Pharmacy at 2666 SW 36th St., Fort Lauderdale, FL 33312.Source: Vytora Health's about page; Vytora Health's website.
S4PASSEvery compounded product page and the answers state that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality.Source: Vytora Health's semaglutide page; Vytora Health's sermorelin page; Vytora Health's website.
S5FAILNo certificate of analysis or lot document is published on the product pages, the answers, the terms or the safety information page.Source: Vytora Health's semaglutide page; Vytora Health's FAQ; Vytora Health's safety information page.
S6FAILNo address is printed for Vytora Health LLC. The contact page gives only an email address and a form, the terms and the privacy policy name the company with an email address, and the about page prints addresses only for the medical group and the two pharmacies.Source: Vytora Health's contact page; Vytora Health's terms; Vytora Health's privacy page; Vytora Health's about page.
S7PASSCompounded semaglutide at $179 a month, or $149 a month on a 3-month plan billed $447, and compounded tirzepatide at $249 a month or $199 on a 3-month plan billed $599, on the product pages. The home page answers print tirzepatide at $199 a month on both plans. Sermorelin at $199 a month on the home page and at the top of its own page, while the answer on that page gives $249 a month, or $186 on a 3-month plan billed $559. The NAD+ injection at $249 a month or $200 on a 3-month plan, and brand Mounjaro and Zepbound at $1,399 a month. The about page gives a starting price of $180 a month and the home page $149.Source: Vytora Health's semaglutide page; Vytora Health's tirzepatide page; Vytora Health's sermorelin page; Vytora Health's NAD+ page; Vytora Health's Zepbound page; Vytora Health's website.
S8PASSNo FDA warning letter names Vytora Health or Vytora Health LLC, and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, compounded sermorelin injection, compounded NAD+ injection, brand Mounjaro, brand Zepbound.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.